Every 10-Q that Tenaya Therapeutics, Inc. (TNYA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TNYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNYA filings page.
Tenaya Therapeutics reported Q2 2026 collaboration revenue of $1,110 (in thousands), its first reported revenue, primarily from a new multi-target research agreement with Alnylam and related collaborations. Total operating expenses rose 88% to $45,198 (in thousands), driven by a $21,821 (in thousands) impairment on its decommissioned Genetic Medicine Manufacturing Center and a $1,368 (in thousands) loss on lease termination, partly offset by lower research and development and general and administrative spending.
The company recorded a Q2 net loss of $43,393 (in thousands) and a six-month net loss of $62,665 (in thousands), compared with $23,283 (in thousands) and $50,147 (in thousands) in 2025. Net cash used in operating activities was $22,786 (in thousands) for the first half, and cash and cash equivalents were $78,085 (in thousands) as of June 30, 2026. Management expects existing cash to fund operations for at least 12 months after filing. Tenaya continues to advance three lead programs: TN-201 and TN-401, AAV9-based gene therapies for genetically defined cardiomyopathies with interim data showing structural, arrhythmia and symptom improvements, and TN-301, an oral HDAC6 inhibitor being positioned for proof-of-activity trials in heart failure with preserved ejection fraction and Duchenne muscular dystrophy.
Tenaya Therapeutics reported a smaller quarterly loss while adding its first collaboration revenue and a major new research partnership. For the three months ended March 31, 2026, net loss was $19.3 million, improving from $26.9 million a year earlier as research and development and general and administrative expenses fell about 30% and 16%, respectively. The company ended the quarter with $80.9 million in cash and cash equivalents and believes this will fund operations for at least twelve months. Tenaya recorded $0.2 million of collaboration revenue and set up $10.4 million of contract liabilities tied mainly to a new multi-target cardiovascular discovery collaboration with Alnylam, which includes a fixed $10.0 million upfront platform access fee and potential milestones of up to $1.1 billion. Management continues to focus spending on its three lead programs TN-201, TN-401 and TN-301 while progressing early-stage pipeline and maintaining one operating segment.
Tenaya Therapeutics (TNYA) reported Q3 2025 results. Net loss was $20.3 million, improving from $25.6 million a year ago, as operating expenses fell to $20.9 million from $26.7 million. Research and development declined to $15.4 million and general and administrative to $5.6 million. Interest income was $0.7 million.
Cash and cash equivalents were $56.3 million, with total assets of $105.0 million and stockholders’ equity of $82.9 million as of September 30, 2025. For the nine months, net loss was $70.4 million versus $87.3 million in 2024. The company completed a March 2025 follow‑on offering with net proceeds of approximately $48.8 million and raised $0.9 million via at‑the‑market sales in January. An SVB loan agreement provides the right to draw $10.0 million through December 31, 2025, with up to an additional $20.0 million at the lender’s discretion.
Programs advanced with interim TN‑201 data presented in November; the FDA placed MyPEAK‑1 on clinical hold to standardize monitoring and immunosuppression protocol activities. Tenaya recognized $1.5 million from an $8.0 million CIRM grant for TN‑401 and recorded $1.2 million related to a 2025 workforce reduction. The company believes existing resources, potential loan availability, and recent warrant exercises will fund operations for at least twelve months following filing. Shares outstanding were 166,505,885 as of November 4, 2025.